Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a European leader in epigenetics, focusing on personalized medicine for CNS disorders and oncology [3] Company Events - Oryzon management will participate in several upcoming events, including the Drug Discovery Innovation Programme on September 25-26 in Barcelona, and the Paris Midcap Event from September 30 to October 1 [1][2] - Additional events include the BME Investor Access Event on October 7 in Paris, BIOSPAIN 2025 from October 7-9 in Barcelona, and the 25th Sachs Annual Biotech in Europe Forum on October 8-9 in Basel, where Oryzon will present on October 8 at 13:45 CET [2] Company Overview - Founded in 2000 in Barcelona, Oryzon has a strong clinical portfolio featuring two LSD1 inhibitors: vafidemstat, which is Phase III-ready for CNS, and iadademstat, currently in Phase II for oncology [3] - The company is also developing ORY-4001, a clinical candidate targeting HDAC-6 for potential applications in CMT and ALS, alongside a robust platform for biomarker identification and target validation for various diseases [3]

[μουσική] [χειροκρότημα] [χειροκρότημα] Καλησπέρα σας. Έχετε κάνει ποτέ μια εξέταση και φοβηθήκατε να δείτε το αποτέλεσμα Μπορεί να ήτανε κάτι απλό, μια γενική αίματος ή κάτι λίγο πιο σοβαρό, μια μικρή βιοψία. Εκείνη στιγμή που ο φόβος να μάθεις ξεπερνάει την ανάγκη να ξέρεις.Τώρα φανταστείτε πως η εξέταση αυτή δεν αφορά το παρόν, αλλά το μέλλον σας. Πώς θα νιώθατε αν ξέρετε ότι έχετε για παράδειγμα 60% αυξημένο κίνδυνο να εμφανίσετε καρδιακιακή νόσο ή 40% μεγαλύτερη πιθανότητα για αλzχάμε στα 58 σας θα θέλ ...

Hello everyone. The first time I touched a calculator was at the age of 16. My father, a first generation entrepreneur, taught me that if you have to really work through the world, you have to learn to figure things on your own.My life then became an entire canvas of how I looked at everything with respect to equations, mathematics and numbers. And what I'm going to walk you all through today is the fascinating world of biology that I will try and explain through numbers. We are swimming in an information a ...

Core Insights - Interpace Biosciences presented two scientific posters at the 2025 American Thyroid Association Annual Meeting, showcasing advancements in thyroid nodule testing and risk stratification [2][3][7] Group 1: Scientific Findings - The first poster demonstrated that 86% of previously insufficient thyroid FNA cases yielded successful molecular results using Interpace's ThyGeNEXT + ThyraMIRv2 testing from archival cytology slides, reducing the need for repeat FNAs [3][7] - The second poster reported on 28,144 indeterminate (Bethesda III/IV) nodules tested, revealing that ThyGeNEXT identified BRAF V600E-like alterations in approximately 4%-6% and RAS-like alterations in about 19%, with 76%-77% being mutation-negative [3][7] - ThyraMIRv2 microRNA profiling further refined malignancy risk, classifying over 90% of mutation-negative nodules as low risk, thus aiding clinical decision-making [3][4] Group 2: Clinical Implications - The integration of archival cytology slides in testing has shown practical advantages, enabling actionable molecular results and clearer patient care guidance [3][7] - The combination platform of ThyGeNEXT and ThyraMIRv2 supports more informed clinical decisions, particularly in managing RAS-like and mutation-negative indeterminate nodules [4][6] Group 3: Company Overview - Interpace Biosciences is positioned as an emerging leader in personalized medicine, offering specialized services from early diagnosis to targeted therapeutic applications [5][6] - The company provides clinically useful molecular diagnostic tests and bioinformatics services to evaluate cancer risk, leveraging advanced technology for improved patient management [6][8]

Core Insights - Oculis Holding AG is set to present results from its late-stage clinical trials, including the Phase 2 ACUITY trial for Privosegtor (OCS-05) and expanded data from the Phase 3 DIAMOND program for OCS-01 eye drops, at several upcoming ophthalmology conferences [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a late-stage clinical pipeline that includes OCS-01 for diabetic macular edema (DME) and Privosegtor for acute optic neuritis [22] Clinical Trial Highlights - The Phase 2 ACUITY trial for Privosegtor (OCS-05) demonstrated clinically meaningful visual function improvement and anatomical neuroprotection in patients with acute optic neuritis, indicating potential applications in various retinal and neurological conditions [3][19] - The Phase 3 DIAMOND program for OCS-01 eye drops aims to evaluate efficacy and safety in DME patients, with over 800 patients enrolled across two pivotal trials [18] Upcoming Presentations - Oculis will present at the Ophthalmology Futures Retina Forum and the EURETINA Congress, with specific sessions focusing on the efficacy and safety outcomes of OCS-01 in DME, highlighting its potential benefits for different patient profiles [2][9][10] Awards and Recognition - The annual Ramin Tadayoni Award, established by EURETINA in partnership with Oculis, will be announced during the EURETINA opening ceremony, recognizing outstanding postgraduate scholars in retinal disease research [4]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] - The management team will participate in several investor conferences in September 2025, including the Wells Fargo Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference [2][3] Company Overview - Oculis has a differentiated late-stage clinical pipeline with three core product candidates: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [5] - The company is headquartered in Switzerland and has operations in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [5] Upcoming Events - Key events include: - Wells Fargo Healthcare Conference from September 3-5 in Boston, U.S. [2] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10 in New York, U.S. [3] - Baird Global Healthcare Conference on September 9-10 in New York, U.S. [3] - Pareto Securities 16th Annual Healthcare Conference on September 16 in Stockholm, Sweden [3] - Leerink Partners Biopharma Summit from September 17-19 in Healdsburg, U.S. [4] - The company will be available for one-on-one meetings during these conferences [4]

Core Insights - Oculis Holding AG reported strong progress in its clinical pipeline, focusing on unmet medical needs in ophthalmology and neuro-ophthalmology, with significant advancements in its key product candidates [2][4][16] Clinical Development - OCS-01 is in pivotal Phase 3 DIAMOND trials, fully enrolled with over 800 patients across 119 global sites, aiming to be the first eye drop treatment for diabetic macular edema (DME), with topline results expected in Q2 2026 [4][5] - Privosegtor (OCS-05) has shown promising Phase 2 ACUITY trial results in acute optic neuritis, indicating significant improvements in visual function and neuroprotective benefits, with plans for a Phase 2/3 trial expected to initiate in 1H 2026 [4][5] - Licaminlimab (OCS-02) is preparing for a genotype-based Phase 2/3 trial in dry eye disease, expected to start in 2H 2025, following positive results from previous studies [4][5] Financial Overview - As of June 30, 2025, Oculis reported cash, cash equivalents, and short-term investments totaling $201.3 million, providing a cash runway into early 2028 [4][6] - Research and development expenses for Q2 2025 were $18.1 million, a decrease from $18.2 million in Q2 2024, primarily due to the timing of completed trials [6][13] - The year-to-date net loss for the first half of 2025 was $67.9 million, compared to $41.5 million for the same period in 2024, driven by advancements in clinical programs and adjustments in warrant liabilities [6][14] Market Potential - DME affects approximately 37 million people globally, representing a market opportunity of around $5 billion, highlighting the significant unmet medical needs for early intervention [5] - The neuroprotective potential of Privosegtor opens opportunities for various neuro-ophthalmology and neurology indications, addressing high unmet needs in these areas [5][16]

Core Points - Eagle Pharmaceuticals, Inc. will hold its 2025 Annual Meeting of Stockholders on October 17, 2025 [1] - The record date for stockholders to participate in the meeting is set for August 18, 2025, at 5 p.m. Eastern Time [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [3] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [3] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [3] - The oncology and critical care pipeline includes product candidates aimed at addressing underserved therapeutic areas across multiple disease states [3] - The company focuses on developing medicines that could be integrated into the personalized medicine paradigm in cancer care [3]

Core Insights - Oculis Holding AG is participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, highlighting its focus on ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs [1][4] Company Overview - Oculis is a global biopharmaceutical company with a focus on innovations for ophthalmic and neuro-ophthalmic conditions [4] - The company has a differentiated late-stage clinical pipeline that includes three core product candidates: - OCS-01, an eye drop in pivotal registration studies aimed at becoming the first non-invasive topical treatment for diabetic macular edema - Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potential applications in various neuro-ophthalmic and neurological diseases - Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, developed with a genotype-based approach for personalized medicine in dry eye disease [4] Upcoming Events - Sylvia Cheung, CFO of Oculis, will present a corporate update available for replay via webcast at 7:00am ET - Snehal Shah, President of R&D, will participate in a live panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET, which will also be available for replay [5]

MADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that Maxim LLC, a U.S.-based investment bank, has initiated research coverage of the company, effective July 18, 2025. This milestone reflects Oryzon's ongoing commitment to transparency and proactive communication with the investment community. Over the years, the company has consistently ...